SCHEMBL2663009

SCHEMBL2663009

O=C(O)CCNC(=O)c1ccc(CN(CCC(c2ccccc2)c2ccccc2)C(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 5/20 0.79
GLP1R P43220 1/20 0.79
TMEM97 Q5BJF2 4/20 0.52
SIGMAR1 Q99720 4/20 0.52
EPHX2 P34913 2/20 0.47
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
HDAC1 Q13547 4/20 0.45
HDAC6 Q9UBN7 4/20 0.45
GCG P01275 1/20 0.45
TPSAB1 Q15661 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
CYP1A2 P05177 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13800474 0.82 GCGR (0.61) GCGRGLP1RTMEM97SIGMAR1EPHX2
SCHEMBL2662956 0.80 GCGR (0.61) GCGRGLP1REPHX2HDAC1HDAC6
SCHEMBL2663347 0.79 GCGR (0.56) GCGRGLP1RTMEM97SIGMAR1HDAC1
SCHEMBL2663152 0.78 GCGR (0.58) GCGRGLP1RTMEM97SIGMAR1EPHX2
SCHEMBL2663205 0.77 GCGR (0.57) GCGRGLP1REPHX2GCGTPSAB1
SCHEMBL4618812 0.77 EPHX2 (0.79) EPHX2CNR1CNR2TPSAB1CYP1A2
SCHEMBL4087887 0.76 GCGR (0.52) GCGRGLP1RTMEM97SIGMAR1HDAC1
SCHEMBL4092836 0.75 GCGR (0.62) GCGRGLP1RGIPR
SCHEMBL5625471 0.75 CYP1A2 (0.66) HDAC1HDAC6GCGNPC1RAB9A
SCHEMBL4081595 0.74 GCGR (0.80) GCGRGLP1RTMEM97SIGMAR1GIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.